Search Results

You are looking at 221 - 230 of 384 items for :

  • "Neutropenia" x
  • Refine by Access: All x
Clear All
Full access

Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

William G. Wierda, Jennifer Brown, Jeremy S. Abramson, Farrukh Awan, Syed F. Bilgrami, Greg Bociek, Danielle Brander, Matthew Cortese, Larry Cripe, Randall S. Davis, Herbert Eradat, Bita Fakhri, Christopher D. Fletcher, Sameh Gaballa, Muhammad Saad Hamid, Brian Hill, Paul Kaesberg, Brad Kahl, Manali Kamdar, Thomas J. Kipps, Shuo Ma, Claudio Mosse, Shazia Nakhoda, Sameer Parikh, Andrew Schorr, Stephen Schuster, Madhav Seshadri, Tanya Siddiqi, Deborah M. Stephens, Meghan Thompson, Chaitra Ujjani, Riccardo Valdez, Nina Wagner-Johnston, Jennifer A. Woyach, Hema Sundar, and Mary Dwyer

>65 years. 118 The incidence of severe neutropenia and infections was significantly more frequent in the FCR arm, especially among patients >65 years, and the incidences of secondary acute myeloid leukemia or myelodysplastic syndrome were also

Full access

Non–Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology

Gregory J. Riely, Douglas E. Wood, David S. Ettinger, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Malcolm DeCamp, Aakash P. Desai, Thomas J. Dilling, Jonathan Dowell, Gregory A. Durm, Scott Gettinger, Travis E. Grotz, Matthew A. Gubens, Aditya Juloori, Rudy P. Lackner, Michael Lanuti, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C. Mullikin, Thomas Ng, Dawn Owen, Dwight H. Owen, Sandip P. Patel, Tejas Patil, Patricio M. Polanco, Jonathan Riess, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C. Yang, Edwin Yau, Kristina M. Gregory, and Lisa Hang

statistically significant difference in OS was reported in the interim analysis. The most common grade 3 or higher AEs were neutropenia, thrombocytopenia, anemia, and leukopenia. Multiple studies have shown that other single-agent EGFR inhibitors and

Full access

Multiple Myeloma, Version 2.2016

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

of patients in both groups. Grade 3 or 4 toxicities of lenalidomide and dexamethasone were hematologic, mainly neutropenia (14.6% vs 0.6%; P <.001); the most common toxicities in thalidomide and dexamethasone were venous thromboembolism (VTE) (15

Full access

Gastric Cancer: A Primer on the Epidemiology and Biology of the Disease and an Overview of the Medical Management of Advanced Disease

Manish A. Shah and David P. Kelsen

= .01). However, although the toxicity observed with DCF was anticipated, it was still of concern. Specifically, 82% of patients developed grade 3/4 neutropenia, with 29% experiencing febrile neutropenia. 43 The DCF regimen showed a significant

Full access

NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022

Featured Updates to the NCCN Guidelines

Natalie S. Callander, Muhamed Baljevic, Kehinde Adekola, Larry D. Anderson Jr, Erica Campagnaro, Jorge J. Castillo, Caitlin Costello, Srinivas Devarakonda, Noura Elsedawy, Matthew Faiman, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Michaela Liedtke, Thomas Martin, James Omel, Douglas Sborov, Kenneth Shain, Keith Stockerl-Goldstein, Donna Weber, Ryan A. Berardi, Rashmi Kumar, and Shaji K. Kumar

occurring hematologic grade 3 or 4 treatment-related adverse events in the daratumumab/pomalidomide/dexamethasone arm were neutropenia (64.3%), anemia (17.9%), and thrombocytopenia (14.3%). 14 An open-label, multicenter phase III study (APOLLO

Full access

Sequencing of Treatment in Advanced Unresectable Colorectal Cancer

Jean L. Grem

.7%), venous thromboembolism (4.7% vs 2.9%), neutropenia (16.2% vs 12.7%), mucositis (3.2% vs 1.0%), and diarrhea (10.0% vs 8.3%). Table 2 Clinical Results From Randomized Phase III Trials Involving Chemotherapy Plus Bevacizumab Regimens in First

Full access

Optimizing Stem Cell Mobilization: Lessons Learned

Pamela S. Becker

-filgrastim is indicated to reduce the duration of severe neutropenia in patients with nonmyeloid malignancies receiving myelosuppressive chemotherapy drugs associated with a clinically significant incidence of febrile neutropenia. Tbo-filgrastim is approved as a

Full access

NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021

Featured Updates to the NCCN Guidelines

Daniel A. Pollyea, Dale Bixby, Alexander Perl, Vijaya Raj Bhatt, Jessica K. Altman, Frederick R. Appelbaum, Marcos de Lima, Amir T. Fathi, James M. Foran, Ivana Gojo, Aric C. Hall, Meagan Jacoby, Jeffrey Lancet, Gabriel Mannis, Guido Marcucci, Michael G. Martin, Alice Mims, Jadee Neff, Reza Nejati, Rebecca Olin, Mary-Elizabeth Percival, Thomas Prebet, Amanda Przespolewski, Dinesh Rao, Farhad Ravandi-Kashani, Paul J. Shami, Richard M. Stone, Stephen A. Strickland, Kendra Sweet, Pankit Vachhani, Matthew Wieduwilt, Kristina M. Gregory, Ndiya Ogba, and Martin S. Tallman

–lowering agent. 45 Venetoclax and HMAs have been shown to induce prolonged cytopenias even after achieving remission, and neutropenia is a dominant treatment-related toxicity associated with this combination of agents. 48 During the first cycle, the panel

Full access

Selecting Targeted Therapies for Patients With Renal Cell Carcinoma

Elizabeth R. Plimack and Gary R. Hudes

have similar efficacy with a more favorable toxicity profile than sunitinib, with lower rates of hand-foot syndrome, fatigue, and neutropenia, but higher rates of hypertension and hepatic enzyme elevation. 12 , 19 This hypothesis has been tested in a

Full access

NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Featured Updates to the NCCN Guidelines

Shaji K. Kumar, Natalie S. Callander, Jens Hillengass, Michaela Liedtke, Muhamed Baljevic, Erica Campagnaro, Jorge J. Castillo, Jason C. Chandler, Robert F. Cornell, Caitlin Costello, Yvonne Efebera, Matthew Faiman, Alfred Garfall, Kelly Godby, Leona Holmberg, Myo Htut, Carol Ann Huff, Yubin Kang, Ola Landgren, Ehsan Malek, Thomas Martin, James Omel, Noopur Raje, Douglas Sborov, Seema Singhal, Keith Stockerl-Goldstein, Carlyn Tan, Donna Weber, Alyse Johnson-Chilla, Jennifer Keller, and Rashmi Kumar

%). 21 Rates of pneumonia, neutropenia, and leukopenia were higher in patients receiving daratumumab. 21 Based on the results of this study, the FDA approved the use of daratumumab/lenalidomide/dexamethasone in this setting. Carfilzomib